Since ID93/GLA-SE was developed as a targeted BCG-prime booster vaccine, in the present study, we evaluated the protective efficacy of ID93/GLA-SE as a boost to a BCG-prime against the hypervirulent Mycobacterium tuberculosis (Mtb) K challenge to provide further information on the development and application of this vaccine candidate. Boosting BCG with the ID93/GLA-SE vaccine significantly reduced bacterial burden at 16 weeks post-challenge while the BCG vaccine alone did not confer significant protection against Mtb K. The pathological analysis of the lung from the challenged mice also showed the remarkably protective boosting effect of ID93/GLA-SE on BCG-immunised animals. Moreover, qualitative and quantitative analysis of the immune responses following ID93/GLA-SE-immunisation demonstrated that ID93/GLA-SE was able to elicit robust and sustained Th1-biased antigen-specific multifunctional CD4+ T-cell responses up to 16 weeks post-challenge as well as a high magnitude of an antigen-specific IgG response. Our findings demonstrate that the ID93/GLA-SE vaccine candidate given as a BCG-prime boost regimen confers a high level of long-term protection against the hypervirulent Mtb Beijing infection. These findings will provide further and more feasible validation for the potential utility of this vaccine candidate particularly in East-Asian countries, with the predominance of the Beijing genotype, after BCG vaccination.
Tuberculosis (TB), caused by Mycobacterium tuberculosis (Mtb), is the number one infectious disease causing human death in the world. In 2017, TB ranked as one of the top ten killers, causing an estimated 10 million new cases with 1.6 million people having died of TB disease. In addition, approximately 1.7 billion people, equivalent to roughly 23% of the global population, are estimated to harbor a latent TB infection (LTBI) and therefore carry the risk of progressing to active TB disease during their lifetime. The global emergence and spread of Mtb strains resistant to one or more front-line TB drugs also contributes to the challenges of treating these burdensome infections1.
The WHO End TB Strategy, has put forth priorities for Mtb control with the ambitious target of reducing global TB disease burden. However, subsequent reporting on TB disease trends are to date inadequate to meet these goals1. Among important TB control measures, the development of novel more effective TB vaccines is one such measure urgently needed to archive this goal.
In 2018, the clinical efficacy trials of two TB multi-antigenic subunit vaccines have demonstrated promising results and have helped to advance the experimental design strategies in the TB vaccine field and candidate pipeline. First, the H4:IC31 candidate was evaluated as a prevention of infection (prophylactic) strategy in high-transmission risk adolescents2. In this trial, the H4:IC31 vaccination reduced the rate of sustained QuantiFERON-TB Gold In-tube assay conversion, which may reflect sustained Mtb infection, with an efficacy of 30.5% along with no serious adverse events. Second, the M72/AS01E vaccine candidate was evaluated as a prevention of TB disease trial in Mtb-infected, healthy adults3.
Interestingly, the two subunit vaccine candidates mentioned above have three common properties; (1) multi-antigenic protein vaccine produced as a single fusion protein, (2) formulated in their own unique adjuvants, and (3) evaluated in Mycobacterium bovis Bacillus Calmette–Guérin (BCG)-vaccinated healthy populations in TB endemic regions, mainly in South African countries. In addition, as with most vaccine candidates, the two subunit vaccines were evaluated and optimised in a variety of animal models prior to advancing into clinical trials4,5,6,7,8,9. Moreover, both vaccine candidates effectively boosted a BCG-induced immune response with the maintenance of a long-term protection and persistent Th1-biased multifunctional CD4+ T-cell responses in preclinical TB models4,9.
Likewise, novel subunit vaccine candidate ID93, which has similar properties as the two above-mentioned vaccine candidates including a multi-antigenic fusion protein combined with a synthetic TLR4 glucopyranosyl lipid adjuvant formulated in a stable oil-in-water emulsion (GLA-SE), has entered into clinical trials. Recently reported from a phase 1 clinical trial, an acceptable safety profile and durable Th1-immunogenicity response was attributed to ID93/GLA-SE given to previously BCG-vaccinated healthy adults10.
Previously, our group demonstrated that vaccination with the ID93/GLA-SE candidate induces a robust reduction of bacterial burden against challenge with the hypervirulent Mtb K/Beijing clinical isolate from a TB outbreak in high schools of South Korea11. Protection with this vaccine was characterised by pulmonary Th1-polarised T-cell immune responses in head-to-head comparison between BCG and the ID93/GLA-SE vaccine in a standard mouse model12. In a separate manuscript, the ID93/GLA-SE vaccine was shown to elicit protection against Mtb W/Beijing HN878 and provide long-lived vaccine-specific Th1-type T-cell immunity in a standard mouse model13, which also included BCG vaccination as a comparator. These findings support the potential use of this vaccine candidate specifically in East-Asian countries where Beijing family strains are predominant14. In addition, the Mtb Beijing lineage strains are expanding globally with the massive spread of multidrug-resistant TB more rapidly than other lineages15, indicating that evaluation of vaccine candidates against the Beijing family in relevant preclinical models is urgently required and may significantly impact global health16. Thus, both investigations strengthen the rationale for evaluating the long-lived efficacy of subunit TB vaccine candidates, like ID93/GLA-SE, against a clinically relevant hypervirulent Mtb isolate in an accessible preclinical animal model.
BCG, the only licensed vaccine against TB, is given to neonates or young children in many countries even though variable and waning efficacy of protection against pulmonary TB has been observed across several clinical studies17,18. Nevertheless, recent clinical meta-analyses studies have demonstrated that individuals who are relatively naïve to mycobacterial exposure prior to BCG vaccination are associated withenhanced efficacy endpoints19, and significant BCG-induced protection against severe disseminated Mtb infection supports its use20. In addition, two promising multi-antigenic subunit vaccine candidates, H4:IC31 and M72/AS01E, mentioned above2,3, were evaluated as a BCG booster vaccine in clinical trials. Thus, although BCG is unable to eradicate TB disease when given alone, we propose that leveraging BCG in a prime-boost regimen may provide a promising vaccine strategy for the prevention of TB disease.
The capacity of T-cells to be expanded and differentiated into effector T-cells from central memory T-cells in response to BCG stimulation wanes with increased age in healthy children, suggesting that booster vaccines should be considered to maintain the antigen-specific T-cells and possibly enhance the duration of protection afforded by BCG21. For these reasons, in the current study, we evaluated protective efficacy of ID93/GLA-SE as a BCG-prime booster vaccine against Mtb K to provide further and more feasible validation.
Although ID93/GLA-SE TB vaccine candidate is currently under evaluation in human clinical trials and has been tested in numerous animal models22,23,24 to our knowledge, evaluation of this TB vaccine as a boost to a BCG-prime in a long-term standard mouse TB model has not been previously reported. For these reasons, in the current study, we evaluated protective efficacy of ID93/GLA-SE as a BCG-prime booster vaccine against Mtb K in a murine model to provide further and more feasible validation of this subunit vaccine candidate.
Antigen-specific immune responses following ID93/GLA-SE immunisation in BCG-vaccinated mice
We previously showed prophylactic efficacy of ID93/GLA-SE vaccine candidate, in the absence of BCG priming, where mice exhibited remarkable reduction of bacterial burden in the tested organs in addition to significantly attenuated lung inflammation following Mtb K infection12. In addition, ex vivo re-stimulation of cells from ID93/GLA-SE immunised mice with ID93 produced substantial IFN-γ in both lung and spleen in a dose-dependent manner12. In the present study, we show antigen-specific immune responses including cellular and humoral responses in BCG-vaccinated mice followed by immunisation with ID93/GLA-SE, where lung and spleen cells were re-stimulated with ID93 or PPD, and immune responses were compared with those of BCG vaccination alone control group (Figs 1 and 2, Supplementary Figs S2–S4).
After ex vivo stimulation of lung or spleen cells with ID93, cells from BCG-primed, ID93/GLA-SE boosted mice produced statistically significant polyfunctional T-cell responses including increased frequencies and absolute numbers of triple-positive (p < 0.001 for lung and p < 0.01 for spleen) and double-positive (p < 0.005 for lung and p < 0.05 for spleen) T-cells producing IFN-γ plus TNF-α and/or IL-2. In contrast, BCG immunised mice produced marginal T-cell responses in both organs (Figs 1 and 2). However, no differences in T-cell response between BCG-immunised group or in the BCG-primed, ID93/GLA-SE boosted group were detected in response to PPD ex vivo stimulation (Supplementary Figs S2 and S3), indicating that T-cell responses following ID93/GLA-SE immunisation were elicited in an ID93-specific manner prior to Mtb challenge. No increase of multifunctional CD8+ T-cell response was observed in response to either ID93 or PPD stimulation (data not shown).
Next, four weeks after the final immunisation antigen-specific antibody responses to PPD or ID93 were assessed in each group to determine whether immunisation elicited humoral responses. The ID93-specific IgG responses, including IgG1 and IgG2c, were significantly pronounced in the BCG-primed ID93/GLA-SE–boosted group compared to the BCG alone group (p < 0.0001) (Supplementary Fig. S4A). Interestingly, PPD-specific IgG2c in the sera from the BCG-primed ID93/GLA-SE–boosted group was detected (Supplementary Fig. S4B). Thus, these results show that ID93/GLA-SE immunisation in BCG-primed animals strongly elicit ID93-specific multifunctional CD4+ T-cell responses both in lung and spleen and elicit a potent antibody response, while BCG induced immune responses were limited in response to both antigens.
Long-lasting protective efficacy following challenge with Mtb K in BCG-primed mice boosted with the ID93/GLA-SE vaccine candidate
To compare the protective efficacy, in terms of reduction in bacterial load in mice, bacterial burdens of each group of mice were analysed at 16 weeks after challenge. Bacterial CFU in the lungs of BCG immunised mice showed no significant reduction against Mtb K strain challenge (Fig. 3A) at 16 weeks post-infection. However, ID93/GLA-SE significantly reduced the number of viable bacteria in the lungs compared to the infection control and to BCG only groups 16 weeks after challenge (p < 0.01 for both infection control and BCG control). The bacterial burden in spleen also showed similar pattern to CFU in lungs (Fig. 3A). Overall, the animals receiving ID93/GLA-SE immunisation following a BCG-prime showed long-term protective efficacy against K strain challenge in terms of bacterial reduction while BCG vaccination did not (Fig. 3A).
Reduced lung inflammation following challenge with Mtb K in BCG-primed, ID93/GLA-SE boosted mice
One characteristic of Mtb K infection in C57BL/6 mice is the induction of exacerbated lung pathology 8 weeks after infection compared to Mtb H37Rv25. To evaluate protection against the extensive lung inflammation observed following infection with Mtb K, lungs were harvested from mice immunised with ID93/GLA-SE vaccination following priming with BCG, and lung pathology was assessed. To measure the extent of lung inflammation, histological preparations from each mouse were stained with H&E and the affected areas of inflammation relative to the total lung area were analysed.
Compared to the infection control and BCG-vaccination group, mice primed with BCG and boosted with ID93/GLA-SE had remarkably decreased granuloma-like lesions and reduced cellularity and size of the lungs when examined by gross pathology (Fig. 3B). Interestingly, the BCG-primed, ID93/GLA-SE boosted immunisation group showed significantly reduced inflammation compared to the infection control group (p < 0.001 for inflamed area percentage and p < 0.05 for inflamed area legions) and BCG-vaccination group (p < 0.05 for inflamed area percentage and p < 0.05 for inflamed area legions) in terms of inflammatory areas impacting the lung (Fig. 3C). Thus, ID93/GLA-SE immunisation conferred prevention of severe and extensive lung inflammation compared to that observed following BCG vaccination against Mtb K strain infection.
Long-term maintenance of antigen-specific CD4+ multifunctional Th1 responses after Mtb challenge in BCG-primed, ID93/GLA-SE boosted mice
We recently reported that durable protection of ID93/GLA-SE immunisation-induced anti-TB immunity was correlated with the sustained multifunctional CD4+ T-cell-mediated Th1 immune response after Mtb challenge12,13. To determine whether ID93-specific Th1 responses persisted in the context of the BCG prime, ID93/GLA-SE boosting strategy, we measured immune responses in the lungs of mice after Mtb K strain challenge (Figs 4 and 5). The frequency of ID93-specific triple positive (p < 0.0001 for lung and p < 0.001 for spleen) and double positive (p < 0.001 for lung and p < 0.01 for spleen) multifunctional CD4+ T-cells in the lung and spleen of mice in the BCG-primed, ID93/GLA-SE boosted group was maintained at 16 weeks after challenge with Mtb K (Figs 4 and 5). For PPD stimulation, BCG-primed immune responses seemed to be especially boosted in the lungs, not the spleens, by ID93/GLA-SE vaccination as evidenced by increased frequency of PPD-specific triple positive (p < 0.0001 for lung) and double positive (p < 0.001 for lung) multifunctional CD4+ T-cells (Supplementary Figs S5 and S6).
Next, we investigated cytokine profiles in the lungs and spleens after re-stimulation with ID93 or PPD to determine whether Th1-mediated responses were maintained (Fig. 6 and Supplementary Fig. S7). Th1-associated cytokines including IFN-γ, TNF-α, and IL-2 but not Th2 cytokines, IL-4 and IL-10, were remarkably induced in the lungs from the BCG-primed ID93/GLA-SE boosted group in response to both ID93 (p < 0.0001 for all Th1-associated cytokines) and PPD ex vivo stimulation (p < 0.0001 for IFN-γ, p < 0.001 for TNF-α, and p < 0.05 for IL-2, respectively) (Fig. 6). Interestingly, IL-17A was induced only in the group that received the BCG-prime ID93/GLA-SE boost regimen in response to ID93 (Fig. 6A). No differences in IFN-γ or TNF-α production was detected between the BCG-vaccination group and BCG-prime ID93/GLA-SE boosted group in the spleen in response to either ID93 or PPD stimulation (Supplementary Figs S7A,B). Expression of IL-2, however was increased in response to ID93 in the BCG prime ID93/GLA-SE boosted group (p < 0.05) (Supplementary Fig. S7A).
In the present study, the long-term protective effect of the ID93/GLA-SE vaccine candidate was evaluated against the Beijing family strain, Mtb K, in a BCG prime-boost regimen. The protective immune response against the Mtb K strain, induced by this vaccine regimen, was characterised by a durable Th1-biased host response including antigen-specific CD4+ T-cells concomitantly producing IFN-γ, TNF-α, and IL-2 in both the lung and spleen (Figs 1 and 2) and potentially due to a Th1-biased ID93- and PPD-specific IgG2c humoral response (Supplementary Fig. S4). The effective boosting property of the ID93/GLA-SE vaccine within BCG-immunised mice was supported by a decrease in bacterial counts within the lung and spleen (Fig. 3A). Strikingly, excessive, irregular, and advanced granulomatous inflammation of lung from the infection control and BCG-vaccination groups were shown, whereas small, rounded and contained granulomas were found in the lung of mice vaccinated in mice received with BCG-priming boosting followed by ID93/GLA-SE immunisation (Fig. 3B). Although the ID93/GLA-SE vaccine candidate has been evaluated in many pre-clinical animal models, including a guinea pig model where ID93/GLA-SE was administered as a booster against the reference strain Mtb H37Rv12,13,23, this is the first study to evaluate the boosting effect of this vaccine candidate against a Beijing family strain of Mtb in BCG-immunised mice. The ID93/GLA-SE vaccine, once approved for use, would be particularly beneficial in East-Asian countries where this Beijing genotype is prevalent.
In our previous study, the ID93/GLA-SE vaccine induced protective efficacy when given as a prophylactic vaccine against Mtb K strain infection12, but the protection was less robust compared to the BCG vaccine. However, the improved potential of ID93/GLA-SE as a booster to the BCG vaccine in a prophylactic setting, not only reported in a guinea pig model23 but also shown in this study, suggests that the subunit vaccine is capable of re-stimulating the protective immunity upon BCG vaccination against infection with Mtb (Figs. 3, 4 and 5).
In fact, prior studies have shown that BCG vaccine efficacy is dependent on the infectious Mtb strain type26,27. The clinical isolate in South Korea, Mtb K, is a representative Beijing family strain from a TB outbreak in South Korean high schools11, where most of the students had previously received the BCG vaccine. The infectivity and pathogenicity of the virulent clinical Mtb K isolate has been studied in mice to characterise the differences compared to a standard Mtb H37Rv isolate25. In particular, W/Beijing Mtb strains exhibit an increased virulent phenotype displayed by faster growth, dampened protective Th1 cellular immune responses, and a higher relapse rate than the H37Rv strain in vivo due in part to an expansion of CD4+CD25+Foxp3+ regulatory T-cells compared to the H37Rv strain25,27. Moreover, BCG-efficacy against W/Beijing strains of Mtb wanes over time in animal models27 mimicking human responses to the vaccine.
Although the lack of reliable correlates of protection for TB makes a go/no-go decision for the advancement of TB vaccines difficult, the three multi-antigenic subunit vaccines, already in clinical development (M72/AS01E, H4:IC31, and ID93/GLA-SE), have commonly shown significant induction of Th1-polarised CD4+ T-cell responses characterised by the production of antigen-specific IFN-γ, TNF-α, and IL-228. Furthermore, these vaccines induce protective efficacy in different animal models, measured by reduction in both bacterial CFU and lung inflammation4,9,12,29. The induction of antigen-specific CD4+ Th1 cellular responses after vaccination have therefore supported proof-of-concept for vaccine evaluation in Phase 1 clinical trials10,30,31,32,33,34.
In this study, significant induction of Th1-polarised Ag-specific multifunctional CD4+ T-cell responses and marked increase of Ag-specific humoral response were observed in BCG-vaccinated mice immunised with ID93/GLA-SE (Figs 1, 2 and supplementary Fig. S4). The immunisation conferred long-term protection against the virulent Mtb K, as evidenced by a significant CFU reduction in the lung and spleen, and by preventing excessive lung inflammation (Fig. 3).
It should be noted that long-lasting pulmonary control by prime-boost vaccination with BCG and ID93/GLA-SE against Mtb infection was accomplished (Fig. 3A). An enhanced level of pulmonary protection compared to that seen in the spleens was observed in the lungs of ID93/GLA-SE-boosted mice. First, the aerosol challenge of Mtb may lead to homing of antigen-specific T-cells to the lung engaging effector responses compared to the spleen. Secondly, while ID93-specific multifunctional CD4+ T-cells are induced in both the spleens and lungs of each immunised mouse prior to Mtb challenge (Figs 1 and 2), a larger number of ID93-responding multifunctional CD4+ T-cells appear to be maintained in lungs compared to that observed in the spleens after Mtb challenge (Figs 4 and 5). This suggests that the maintenance of ID93-specific multifunctional T-cell population, particularly in the lungs for at least 16 weeks post-infection may confer improved protection. Thirdly, a significantly higher magnitude of Th1-polarised cytokines such as IFN-γ, IL-2 and TNF-α, not Th2-associated cytokines, are induced following the ex vivo stimulation with both ID93 and PPD from cells in the lungs from ID93/GLA-SE-boosted mice (Fig. 6), but not in spleen except for IL-2 (Supplementary Fig. S7), which could contribute to better protection in the lung. Fourth, in addition to direct protective pulmonary contribution, boosting BCG with ID93/GLA-SE induced antigen-specific antibody responses (Supplementary Fig. S4). Unlike the guinea pigs data23, ID93-specific IgG1 and IgG2c responses were not found to be different in the BCG prime/boosted mouse study, representing an IgG2c/IgG1 mixed antibody response. Notably, PPD-specific IgG2c responses were significantly increased compared to IgG1 responses. This PPD-specific IgG2c biased response may be associated with an enhanced Th1-polarised response contributing to improved BCG primed/boosted protection against Mtb infection. Lastly, ID93-specific IL-17 production in the lungs was notably observed (Fig. 6A). Recently, the protective role of Th17 responses against Mtb has emerged in the literature by controlling Mtb growth and limiting extensive pathology in the lungs during Mtb infection35,36,37,38,39,40,41. In fact, IL-17-producing Th17 cells are considered to be particularly essential in vaccine-mediated immunity35,42 by rapidly recruiting CD4+IFN-γ+ T-cells to the site of infection, leading to earlier control of Mtb35. A previous study has shown that ID93/GLA-SE vaccination can elicit Th17 responses when given intranasally but not through intramuscular injection43. Although induced tissue-resident Th17 responses do not contribute to the protective efficacy in the murine subunit vaccination model43, ID93-specific IL-17 production may contribute to improved vaccine efficacy in animals that received ID93/GLA-SE as a boost in the BCG booster murine model which is employed for the first time (Figs 3 and 6). Nevertheless, the underlying mechanisms associated with improved protection conferred by BCG-primed ID93/GLA-SE boosting vaccination remains to be clearly defined.
Prior studies have shown that mice immunised with the ID93/GLA-SE candidate vaccine generate a Th1-biased response, with antigen-specific polyfunctional CD4+ T-cells. ID93/GLA-SE prophylactic immunisation has led to the protection of mice against challenge with either H37Rv23,44 or a multidrug-resistant TN5904 strain of Mtb23. Furthermore, boosting BCG with ID93/GLA-SE conferred long-term protection accompanied with ameliorated pathology against TB in guinea pig model23. Considering that promising results of heterologous prime/boost regimens such as BCG primed followed by boosting with adjuvanted antigens found in BCG and/or Mtb45,46, ID93 which is composed of antigens found in both Mtb and BCG could be capable of boosting BCG-primed immunity. Based on these results including our study, which strengthen the immunogenicity and protective efficacy of ID93/GLA-SE as a BCG booster, there is the potential for use of this vaccine candidate as a booster vaccine to improve the waning efficacy of the BCG vaccine. Since vaccination of BCG occurs within the first month of birth according to the BCG vaccination policy in South Korea, the efficacy testing of ID93/GLA-SE as a booster vaccine is ongoing in humans. Advances towards TB elimination by preventing Mtb transmission will require strenuous efforts including prevention of disease, where the impact of this BCG prime, ID93/GLA-SE boost vaccine regimen may be especially effective23.
Collectively, the capacity of T-cells to be expanded and differentiated into effector T-cells from central memory T-cells in response to BCG stimulation wanes with the increase of age in healthy children, suggesting that booster vaccines should be considered to maintain the antigen-specific T-cells and possibly enhance the duration of protection afforded by BCG21. ID93/GLA-SE was able to elicit robust and sustained Th1-biased immune responses including antigen-specific multifunctional CD4+ T-cell co-producing IFN-γ, TNF-α, and IL-2 as well as a high magnitude of antigen-specific Th1-biased antibodies. Our findings showed that ID93/GLA-SE vaccine as a BCG-prime booster confers a high level of long-term protection against the hypervirulent Mtb Beijing infection. These findings also showcase the potential utility of this vaccine candidate in East-Asian countries with the predominance of the Beijing genotype after BCG vaccination.
All animal studies were carried out accordingly following the guidelines of the Korean Food and Drug Administration (KFDA). The experimental protocols used in this study were reviewed and approved by the Ethics Committee and Institutional Animal Care and Use Committee (Permit Number: 2015-0041) of the Laboratory Animal Research Center at Yonsei University College of Medicine (Seoul, Korea).
Preparation of Mycobacterium spp
Mtb K strain was obtained from the strain collections at the Korean Institute of Tuberculosis (KIT, Osong, Chungchungbuk-do, Korea). M. bovis BCG (Pasteur strain 1173P2) was kindly provided by Dr. Brosch at the Pasteur Institute (Paris, France). These strains were cultured in Middlebrook 7H9 broth (Difco Laboratories, Detroit, MI) supplemented with 0.02% glycerol and 10% (vol/vol) oleic acid-albumin-dextrose-catalase (OADC, Becton Dickinson, Sparks, MD) for 28 days at 37 °C. Single cell suspensions of each strain were prepared as previously described12.
Animals, immunisation, and challenge protocol
Specific pathogen-free 5-week-old female C57BL/6J mice were purchased from Japan SLC, Inc. (Shijuoka, Japan) and strictly maintained under barrier conditions in a BL-3 biohazard animal facility at the Yonsei University Medical Research Center. The animals were fed a sterile commercial mouse diet and provided with water ad libitum. The mice were monitored daily before and after immunisation and Mtb challenge, and none of the mice showed any clinical symptoms or illness during this experiment.
Immunisation with ID93 formulated in GLA-SE was performed as previously described12. Briefly, mice were immunised with BCG Pasteur 1173P2 via subcutaneous injection (2.0 × 105 CFUs/mouse), then 10 weeks following the BCG immunisation, ID93/GLA-SE vaccine (1 μg ID93 antigen formulated in 5 μg of GLA-SE / injection) was given as a boost, intramuscularly, three times at 3-week intervals (Supplementary Fig. S1A). Four weeks after the final immunisation, the immunised mice were aerogenically challenged with the Mtb K strain as previously described12. Aerosol infection was performed using a Glas-Col aerosol apparatus (Terre Haute, IN, USA) adjusted to achieve an initial infectious dose of 200 CFUs. At 16 weeks post-challenge, mice from each group were euthanised to analyse bacterial load, histopathology, and immune responses including the frequency and number of multifunctional T-cells.
Bacterial enumeration and histopathology
At 16 weeks following Mtb challenge, eight mice per group were euthanised with CO2, and lungs and spleens were homogenised. The number of viable bacteria was determined by plating serial dilutions of the organ homogenates onto Middlebrook 7H11 agar (Difco, USA) supplemented with 10% OADC (Difco, USA) and amphotericin B (Sigma Aldrich, USA). Colonies were counted after 4 weeks of incubation at 37 °C. For histopathological analysis, the middle cross-section from entire superior lobes of the right lung were stained with hematoxylin and eosin (H&E) and assessed for the severity of inflammation. The level of inflammation in the lungs was evaluated using by ImageJ (National Institutes of Health, USA) program, as previously described47. Briefly, for quantitative histopathological analysis of H&E staining, all slides were scanned using an Olympus BX43 microscope 4 × objective (Olympus Optical Co., Tokyo, Japan), and a pathologist assessed and quantified histopathology in a blinded manner. Each slide image per mouse was evaluated with the ToupTek Toup viewer program (Toup View Co., Zhejiang, China) to quantify the total size of the inflamed lesions in each mouse. The measured area is presented as mm2.
Flow cytometry and intracellular cytokine staining
Single cell suspensions (1.5 × 106 cells) from immunised or Mtb-infected mice were stimulated with PPD (2 μg/ml) or ID93 (1 μg/ml) at 37 °C for 2 hours. Then, stimulated-single cell suspensions were further incubated at 37 °C for 10 more hours in the presence of both GolgiPlug and GolgiStop (BD Biosciences). PPD was kindly provided by Dr. Michael Brennan at Aeras (Rockville, MD, USA). Cells were first washed with 2% FBS containing PBS and blocked with anti-CD16/32 (BD Biosciences) at 4 °C for 20 min. After the cells were stained with LIVE/DEADTM Fixable Viability Dye eFluorTM 780 (ThermoFisher Scientific), and surface stained with Brilliant Violet (BV) 421-conjugated anti-CD4, peridinin chlorophyll (PerCP)-Cy5.5-conjugated anti-CD8, phycoerythrin (PE)-conjugated anti-CD44 (BD Biosciences) antibodies at 4 °C for 30 min and were washed. These cells were permeabilised and fixed with the Cytofix/Cytoperm kit (BD Biosciences) at 4 °C for 30 min. Then, cells were washed twice with Perm/Wash (BD Biosciences) and intracellularly stained with allophycocyanin (APC)-conjugated anti-IFN-γ, BV605-conjugated anti-TNF-α and PE-conjugated anti-IL-2 (Biolegend, San Diego, CA, USA) at 4 °C for 30 min. After washing three times with Perm/Wash, cells were fixed with IC Fixation buffer (eBioscience). Then, 2% FBS containing PBS-resuspended cells were analysed on FACSCanto II (BD Biosciences) using the commercially available software program FlowJo (Tree Star, Ashland, OR, USA). Next, the analysed antigen-specific multifunctional T-cells were either represented as percentages among total number of CD4+CD44+ T-cells or described as actual counts of cytokine-producing cells as bar graphs. Gating strategy for flow cytometry analysis is depicted in Supplementary Figure S1B. For pie charts analysis, the values summarise the fractions of triple (3+, purple), double (2+, light jade), and single (1+, grey) CD4+CD44+ T-cell producers of IFN-γ, TNF-α and IL-2 in each immunised group. The mean number of cytokine-positive cells is displayed as pie charts with multiple colour fractions, and the number of the rest of the population in total CD4+CD44+ T-cells was described as a grey fraction in the pie charts.
Antibody titers in serum
96 well plates were coated with 1 μg/ml of PPD or ID93, and Ag-specific IgG, IgG1 and IgG2c responses in serum of immunised mice were measured as previously described48.
Quantification of cytokines
Cytokines in ex vivo-isolated single cells from the lungs and spleens of infected mice were analysed by commercial ELISA kits according to the manufacturers’ instructions after stimulation with the PPD (2 μg/ml) or ID93 (1 μg/ml) for 24 hours at 37 °C. The ELISA was used for detecting IFN-γ, IL-2, IL-17, TNF-α, IL-4 and IL-10 in the culture supernatant. All ELISA kits were purchased from eBioscience, except for the IL-10 ELISA kit (BD Biosciences).
Data for all experiments are presented as the mean ± standard deviation (SD). The significance of differences between samples was assessed by one-way ANOVA after Tukey’s post-test for multiple comparisons in more than three groups or by unpaired t-test in the selected two groups, followed by Shapiro-Wilk normality test using GraphPad Prism version 6.00 for Windows (GraphPad Software, La Jolla California USA, www.graphpad.com). Differences with each value of *p < 0.05, **p < 0.01, ***p < 0.001, or ****p < 0.0001 were considered statistically significant.
Global tuberculosis report 2018. Report No. ISBN 978-92-4-156564-6, (World Health Organization, Geneva, 2018).
Nemes, E. et al. Prevention of M. tuberculosis Infection with H4:IC31 Vaccine or BCG Revaccination. N Engl J Med 379, 138–149 (2018).
Van Der Meeren, O. et al. Phase 2b Controlled Trial of M72/AS01E Vaccine to Prevent Tuberculosis. N Engl J Med 379, 1621–1634 (2018).
Reed, S. G. et al. Defined tuberculosis vaccine, Mtb72F/AS02A, evidence of protection in cynomolgus monkeys. Proc Natl Acad Sci USA 106, 2301–2306 (2009).
Tsenova, L. et al. Evaluation of the Mtb72F polyprotein vaccine in a rabbit model of tuberculous meningitis. Infect Immun 74, 2392–2401 (2006).
Irwin, S. M. et al. Tracking antigen-specific CD8 T lymphocytes in the lungs of mice vaccinated with the Mtb72F polyprotein. Infect Immun 73, 5809–5816 (2005).
Hoang, T. et al. ESAT-6 (EsxA) and TB10.4 (EsxH) based vaccines for pre- and post-exposure tuberculosis vaccination. PLoS One 8, e80579 (2013).
Skeiky, Y. A. et al. Non-clinical efficacy and safety of HyVac4:IC31 vaccine administered in a BCG prime-boost regimen. Vaccine 28, 1084–1093 (2010).
Billeskov, R., Elvang, T. T., Andersen, P. L. & Dietrich, J. The HyVac4 subunit vaccine efficiently boosts BCG-primed anti-mycobacterial protective immunity. PLoS One 7, e39909 (2012).
Penn-Nicholson, A. et al. Safety and immunogenicity of the novel tuberculosis vaccine ID93 + GLA-SE in BCG-vaccinated healthy adults in South Africa: a randomised, double-blind, placebo-controlled phase 1 trial. Lancet Respir Med 6, 287–298 (2018).
Kim, S. J. et al. Transmission of Mycobacterium tuberculosis among high school students in Korea. Int J Tuberc Lung Dis 5, 824–830 (2001).
Cha, S. B. et al. Pulmonary immunity and durable protection induced by the ID93/GLA-SE vaccine candidate against the hyper-virulent Korean Beijing Mycobacterium tuberculosis strain K. Vaccine 34, 2179–2187 (2016).
Baldwin, S. L. et al. Protection and Long-Lived Immunity Induced by the ID93/GLA-SE Vaccine Candidate against a Clinical Mycobacterium tuberculosis Isolate. Clin Vaccine Immunol 23, 137–147 (2016).
Luo, T. et al. Southern East Asian origin and coexpansion of Mycobacterium tuberculosis Beijing family with Han Chinese. Proc Natl Acad Sci USA 112, 8136–8141 (2015).
Merker, M. et al. Evolutionary history and global spread of the Mycobacterium tuberculosis Beijing lineage. Nat Genet 47, 242–249 (2015).
Parwati, I., van Crevel, R. & van Soolingen, D. Possible underlying mechanisms for successful emergence of the Mycobacterium tuberculosis Beijing genotype strains. Lancet Infect Dis 10, 103–111 (2010).
Brewer, T. F. Preventing tuberculosis with bacillus Calmette-Guerin vaccine: a meta-analysis of the literature. Clin Infect Dis 31(Suppl 3), S64–67 (2000).
Colditz, G. A. et al. Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature. Jama 271, 698–702 (1994).
Mangtani, P. et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis 58, 470–480 (2014).
Roy, A. et al. Effect of BCG vaccination against Mycobacterium tuberculosis infection in children: systematic review and meta-analysis. Bmj 349, g4643 (2014).
Whittaker, E., Nicol, M. P., Zar, H. J., Tena-Coki, N. G. & Kampmann, B. Age-related waning of immune responses to BCG in healthy children supports the need for a booster dose of BCG in TB endemic countries. Sci Rep 8, 15309 (2018).
Larsen, S. E. et al. Enhanced Anti-Mycobacterium tuberculosis Immunity over Time with Combined Drug and Immunotherapy Treatment. Vaccines (Basel) 6 (2018).
Bertholet, S. et al. A defined tuberculosis vaccine candidate boosts BCG and protects against multidrug-resistant Mycobacterium tuberculosis. Sci Transl Med 2, 53ra74 (2010).
Coler, R. N. et al. Therapeutic immunization against Mycobacterium tuberculosis is an effective adjunct to antibiotic treatment. J Infect Dis 207, 1242–1252 (2013).
Kim, W. S. et al. Virulence-Dependent Alterations in the Kinetics of Immune Cells during Pulmonary Infection by Mycobacterium tuberculosis. PLoS One 10, e0145234 (2015).
Jeon, B. Y. et al. Mycobacterium bovis BCG immunization induces protective immunity against nine different Mycobacterium tuberculosis strains in mice. Infect Immun 76, 5173–5180 (2008).
Ordway, D. J. et al. Mycobacterium bovis BCG-mediated protection against W-Beijing strains of Mycobacterium tuberculosis is diminished concomitant with the emergence of regulatory T cells. Clin Vaccine Immunol 18, 1527–1535 (2011).
Rodo, M. J. et al. A comparison of antigen-specific T cell responses induced by six novel tuberculosis vaccine candidates. PLoS Pathog 15, e1007643 (2019).
Skeiky, Y. A. et al. Differential immune responses and protective efficacy induced by components of a tuberculosis polyprotein vaccine, Mtb72F, delivered as naked DNA or recombinant protein. J Immunol 172, 7618–7628 (2004).
Leroux-Roels, I. et al. Improved CD4(+) T cell responses to Mycobacterium tuberculosis in PPD-negative adults by M72/AS01 as compared to the M72/AS02 and Mtb72F/AS02 tuberculosis candidate vaccine formulations: a randomized trial. Vaccine 31, 2196–2206 (2013).
Norrby, M. et al. Safety and immunogenicity of the novel H4:IC31 tuberculosis vaccine candidate in BCG-vaccinated adults: Two phase I dose escalation trials. Vaccine 35, 1652–1661 (2017).
Geldenhuys, H. et al. The tuberculosis vaccine H4:IC31 is safe and induces a persistent polyfunctional CD4 T cell response in South African adults: A randomized controlled trial. Vaccine 33, 3592–3599 (2015).
Coler, R. N. et al. The TLR-4 agonist adjuvant, GLA-SE, improves magnitude and quality of immune responses elicited by the ID93 tuberculosis vaccine: first-in-human trial. NPJ Vaccines 3, 34 (2018).
Derrick, S. C., Yabe, I. M., Yang, A. & Morris, S. L. Vaccine-induced anti-tuberculosis protective immunity in mice correlates with the magnitude and quality of multifunctional CD4 T cells. Vaccine 29, 2902–2909 (2011).
Khader, S. A. et al. IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge. Nat Immunol 8, 369–377 (2007).
Wozniak, T. M., Saunders, B. M., Ryan, A. A. & Britton, W. J. Mycobacterium bovis BCG-specific Th17 cells confer partial protection against Mycobacterium tuberculosis infection in the absence of gamma interferon. Infect Immun 78, 4187–4194 (2010).
Scriba, T. J. et al. Distinct, specific IL-17- and IL-22-producing CD4+ T cell subsets contribute to the human anti-mycobacterial immune response. J Immunol 180, 1962–1970 (2008).
Okamoto Yoshida, Y. et al. Essential role of IL-17A in the formation of a mycobacterial infection-induced granuloma in the lung. J Immunol 184, 4414–4422 (2010).
Khader, S. A. et al. IL-23 is required for long-term control of Mycobacterium tuberculosis and B cell follicle formation in the infected lung. J Immunol 187, 5402–5407 (2011).
Freches, D. et al. Mice genetically inactivated in interleukin-17A receptor are defective in long-term control of Mycobacterium tuberculosis infection. Immunology 140, 220–231 (2013).
Gopal, R. et al. Unexpected role for IL-17 in protective immunity against hypervirulent Mycobacterium tuberculosis HN878 infection. PLoS Pathog 10, e1004099 (2014).
Desel, C. et al. Recombinant BCG DeltaureC hly+ induces superior protection over parental BCG by stimulating a balanced combination of type 1 and type 17 cytokine responses. J Infect Dis 204, 1573–1584 (2011).
Orr, M. T. et al. Mucosal delivery switches the response to an adjuvanted tuberculosis vaccine from systemic TH1 to tissue-resident TH17 responses without impacting the protective efficacy. Vaccine 33, 6570–6578 (2015).
Baldwin, S. L. et al. The importance of adjuvant formulation in the development of a tuberculosis vaccine. J Immunol 188, 2189–2197 (2012).
Dietrich, J., Billeskov, R., Doherty, T. M. & Andersen, P. Synergistic effect of bacillus calmette guerin and a tuberculosis subunit vaccine in cationic liposomes: increased immunogenicity and protection. J Immunol 178, 3721–3730 (2007).
Rouanet, C., Debrie, A. S., Lecher, S. & Locht, C. Subcutaneous boosting with heparin binding haemagglutinin increases BCG-induced protection against tuberculosis. Microbes Infect 11, 995–1001 (2009).
Kwon, K. W. et al. Novel vaccine potential of Rv3131, a DosR regulon-encoded putative nitroreductase, against hyper-virulent Mycobacterium tuberculosis strain K. Sci Rep 7, 44151 (2017).
Kwon, K. W. et al. Vaccine efficacy of a Mycobacterium tuberculosis Beijing-specific proline-glutamic acid (PE) antigen against highly virulent outbreak isolates. Faseb j 33, 6483–6496 (2019).
This work was supported by the National Research Foundation of Korea(NRF) grant funded by the Korea government (MSIT) (NRF-2019R1A2C2003204), Republic of Korea and the National Institute of Allergy and Infectious Diseases of the National Institutes of Health, USA (R01AI125160). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Dr. Reed is a founder of, and holds an equity interest in, Immune Design Corp., a licensee of certain rights associated with GLA. Dr. Kwon, Dr. Lee, Dr. Larsen, Dr. Baldwin, Dr. Coler, Dr. Cho, Dr. Ha, and Dr. Shin declare no potential conflict of interest.
Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Kwon, K.W., Lee, A., Larsen, S.E. et al. Long-term protective efficacy with a BCG-prime ID93/GLA-SE boost regimen against the hyper-virulent Mycobacterium tuberculosis strain K in a mouse model. Sci Rep 9, 15560 (2019) doi:10.1038/s41598-019-52146-0